Skip to content

Feed Screener Search Methodology

SEC · FI · BAFIN · AFM · AMF

Pricing Sign in

InsiderLens

Statistics predict. AI explains.

Insider transactions from public regulatory disclosures, aggregated and enriched with deterministic statistical signals. Not investment advice.

Sources

SEC EDGAR · US
FINANSINSPEKTIONEN · SE
BAFIN · DE
AFM · NL
AMF · FR

Product

Methodology
Privacy notice
Object to processing

Feed Screener Search Methodology

Pricing Sign in

Bingham James B. — NextCure, Inc. insider: 1 transactions · InsiderLens

Home / Insiders / Bingham James B.

Bingham James B.

Chief Development Officer at NextCure, Inc. · on record since May 8, 2019

Insider trading activity of Bingham James B.

Transactions on record: 1; since Mar 3, 2020

Open-market buys: 0

Open-market sells: 0

Companies traded: 1; last filing Mar 3, 2020

Figures computed from official regulatory filings — methodology.

Companies where Bingham James B. has traded

NextCure, Inc.1 tx · Mar 3, 2020

Track record of Bingham James B.

Insufficient history for a statistical track record (fewer than 5 open-market buys).

Transaction history of Bingham James B.

Co-insiders of Bingham James B.

Alexandria Venture Investments, LLCNextCure, Inc.
Borgman Anne ElizabethNextCure, Inc.
Canaan Partners X LLCNextCure, Inc.
CANAAN X L.P.NextCure, Inc.
Cobourn Steven P.NextCure, Inc.
Feigal EllenNextCure, Inc.
Guha UdayanNextCure, Inc.

This page republishes public regulatory disclosures. Concerned by this data? Exercise your right to object →

Hainan Simcere Zaiming Pharmaceutical Co., Ltd.NextCure, Inc.

HEALY JAMESNextCure, Inc.

Heller Kevin N.NextCure, Inc.

Houston John GNextCure, Inc.

Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd.NextCure, Inc.

Jones Elaine VNextCure, Inc.

KABAKOFF DAVID SNextCure, Inc.

Khuong Chau QuangNextCure, Inc.

Kundu SouravNextCure, Inc.

Langermann SolNextCure, Inc.

Li JudithNextCure, Inc.

Liu LindaNextCure, Inc.

Mayer TimothyNextCure, Inc.

Mehra AnandNextCure, Inc.

Morrison BriggsNextCure, Inc.

Myint HanNextCure, Inc.

Nicholson Garry ANextCure, Inc.

ORBIMED ADVISORS LLCNextCure, Inc.

OrbiMed Capital GP VI LLCNextCure, Inc.

POWELL MICHAELNextCure, Inc.

Quan Venture Fund II, L.P.NextCure, Inc.

Ren JinshengNextCure, Inc.

Richman MichaelNextCure, Inc.

SHANNON TIMOTHY MNextCure, Inc.

Shaw Kevin G.NextCure, Inc.

Simcere Pharmaceutical Group LtdNextCure, Inc.

Simcere Zaiming, Inc.NextCure, Inc.

Sofinnova Management IX, L.L.C.NextCure, Inc.

Sofinnova Venture Partners IX, L.P.NextCure, Inc.

Tang RenhongNextCure, Inc.

Webster Stephen WNextCure, Inc.

Xu StellaNextCure, Inc.

Company	Filed	Type	Qty	Price	Value · USD	Src
NextCure, Inc.	Mar 3, 2020	AwardD	78,200	0.00 USD	$0	SEC